Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Operating Cash Flow
Cash generated by the company's core business operations during the period.
Immunocore Holdings plcNASDAQ: IMCR
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns negative
Q1 FY2026 operating cash flow was -$13.75M, compared with $435K a year earlier. Trailing-twelve-month operating cash flow was -$24.9M. Over 3 fiscal years it compounded at -45.5% a year.
Context
- Operating cash flow amounted to 2.7% of revenue in FY2025, down 7.8 pp from a year earlier.
- Operating cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly operating cash flow holds near -$13.75M or moves back toward the trailing-twelve-month quarterly average of -$6.22M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
Mixed currencies · from the cash flow
- Latest · FY2025
- (7.97M) USD
- Year-over-year change
- -130.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.97M) | -130.6% |
| FY2024 | 2024-12-31 | 26.06M | — |
| FY2023 | 2023-12-31 | 2.33M | +104.7% |
| FY2022 | 2022-12-31 | (49.21M) | +65.6% |
| FY2021 | 2021-12-31 | (143.11M) | — |
Operating Cash Flow vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -180.1% is the lowest of 10, against a peer median of +53.4%.
- Operating cash flow amounts to 6.5% of revenue for IMCR, versus a peer median of 277.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €736.83M EUR | +139.2% | -68.2% | 27.9% | |
| LTM Jun 2026 | $474M USD | +39.8% | — | 405.1% | |
| LTM Sep 2026 | $287.56M USD | -10.1% | -3.3% | 157.5% | |
| LTM Jun 2026 | $205.81M USD | +53.4% | — | 196.1% | |
| LTM Mar 2026 | €184.13M EUR | +15.3% | — | 493.7% | |
| LTM Mar 2026 | $77.55M USD | +68.6% | +24.2% | 358.8% | |
| LTM Mar 2026 | $69.96M USD | +0.5% | -2.3% | 44.5% | |
| FY2025 | A$62.05M AUD | +78.2% | +27.1% | 1230.2% | |
| FY2025 | €50.67M EUR | +634.8% | +38.3% | 1818.2% | |
| LTM Mar 2026 | $24.9M USD | -180.1% | -45.5% | 6.5% | |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding IMCR) | — | +53.4% | +10.9% | 277.4% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (180.03M) | (52.54M) | (34.32M) | (51.09M) | (26.42M) |
| Depreciation & Amortization | 7.59M | 5.34M | 3.24M | 4.2M | 2.43M |
| Deferred Income Tax | (12.69M) | (3.53M) | 0 | 0 | 11M |
| Stock-Based Compensation | 48.89M | 32.89M | 25.69M | 34.19M | 0 |
| Change in Working Capital | (21.96M) | (24.17M) | 4.58M | 45.13M | (6.92M) |
| Accounts Receivables | (4.86M) | (26.26M) | (14.14M) | (12.35M) | (5.46M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.47M | 4.91M | 2.08M | 7.27M | (1.83M) |
| Other Working Capital | (18.57M) | (2.81M) | 16.64M | 50.21M | 366K |
| Other Non-Cash Items | 15.09M | (7.19M) | 3.14M | (6.38M) | 11.94M |
| Operating Cash Flow | (143.11M) | (49.21M) | 2.33M | 26.06M | (7.97M) |
| Capital Expenditures | (1.39M) | (2.2M) | (4.29M) | (5.17M) | (3.23M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (350M) | (22.32M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 13.39M |
| Other Investing Activities | 106K | 6K | (925.46K) | 44K | 0 |
| Investing Cash Flow | (1.28M) | (2.2M) | (4.29M) | (355.13M) | (12.16M) |
| Debt Repayment | 0 | 0 | 0 | 352.5M | 0 |
| Common Stock Issued | 286.89M | 139.52M | 0 | 6.8M | 9.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 5.93M | 27.18M | (15.42M) | 0 |
| Financing Cash Flow | 288.19M | 145.44M | 27.18M | 343.88M | 9.2M |
| Effect of Forex Changes | 625K | (12.65M) | 6.56M | (1.71M) | 19.81M |
| Net Change in Cash | 144.42M | 81.39M | 31.78M | 13.11M | 8.89M |
| Free Cash Flow | (144.49M) | (51.41M) | (1.97M) | 20.89M | (11.2M) |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.